$ARDX
ARDELYX, INC. Stock $ardx

$ardx Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-Q Financial Statement

#000119312517334997 Filed on November 07, 2017

Income Statement

Concept	2017 Q4	2017 Q3	2016 Q4
Revenue	$42.00M	$0.00	$0.00
YoY Change
Cost Of Revenue	$8.400M
YoY Change
Gross Profit	$33.60M
YoY Change
Gross Profit Margin	80.0%
Selling, General & Admin	$5.480M	$5.860M	$5.270M
YoY Change	3.98%	35.02%	28.85%
% of Gross Profit	16.31%
Research & Development	$17.16M	$15.37M	$26.21M
YoY Change	-34.53%	-38.2%	105.09%
% of Gross Profit	51.07%
Depreciation & Amortization	$670.0K	$730.0K	$400.0K
YoY Change	67.5%	170.37%	37.93%
% of Gross Profit	1.99%
Operating Expenses	$22.64M	$21.23M	$31.48M
YoY Change	-28.07%	-27.31%	86.51%
Operating Profit	$10.96M	-$21.23M
YoY Change		-27.31%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$330.0K	$501.0K	$200.0K
YoY Change	65.0%	196.45%	-266.67%
Pretax Income	$11.29M	-$20.72M	-$31.27M
YoY Change	-136.1%	-28.61%	83.94%
Income Tax	$1.180M	$0.00	$0.00
% Of Pretax Income	10.45%
Net Earnings	$10.11M	-$20.72M	-$31.28M
YoY Change	-132.33%	-28.61%	83.98%
Net Earnings / Revenue	24.07%
Basic Earnings Per Share
Diluted Earnings Per Share	$212.7K	-$436.6K	-$660.3K
COMMON SHARES
Basic Shares Outstanding	47.53M shares	47.45M shares	47.30M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q4	2017 Q3	2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$134.0M	$129.3M	$200.8M
YoY Change	-33.29%	-43.81%	87.69%
Cash & Equivalents	$75.38M	$59.45M	$74.60M
Short-Term Investments	$58.59M	$69.83M	$126.2M
Other Short-Term Assets	$4.900M	$4.300M	$3.200M
YoY Change	53.13%	4.88%	-36.0%
Inventory
Prepaid Expenses
Receivables	$10.80M
Other Receivables	$0.00
Total Short-Term Assets	$149.7M	$133.6M	$204.0M
YoY Change	-26.61%	-42.94%	82.09%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.000M	$8.622M	$8.991M
YoY Change	-11.02%	23.72%	90.85%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$159.0K	$853.0K	$148.0K
YoY Change	7.43%	476.35%	42.31%
Total Long-Term Assets	$8.191M	$9.475M	$9.139M
YoY Change	-10.37%	33.13%	85.94%
TOTAL ASSETS
Total Short-Term Assets	$149.7M	$133.6M	$204.0M
Total Long-Term Assets	$8.191M	$9.475M	$9.139M
Total Assets	$157.9M	$143.1M	$213.1M
YoY Change	-25.91%	-40.7%	82.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.933M	$1.723M	$5.635M
YoY Change	-30.2%	-72.64%	102.92%
Accrued Expenses	$13.20M	$13.30M	$12.90M
YoY Change	2.33%	26.67%	871.39%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$17.87M	$15.73M	$19.20M
YoY Change	-6.93%	-10.82%	148.62%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$720.0K	$741.0K	$779.0K
YoY Change	-7.57%	-6.08%	141.93%
Total Long-Term Liabilities	$720.0K	$741.0K	$779.0K
YoY Change	-7.57%	-6.08%	141.93%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.87M	$15.73M	$19.20M
Total Long-Term Liabilities	$720.0K	$741.0K	$779.0K
Total Liabilities	$18.59M	$16.47M	$19.98M
YoY Change	-6.95%	-10.62%	148.35%
SHAREHOLDERS EQUITY
Retained Earnings	-$278.2M	-$288.3M	-$213.9M
YoY Change	30.08%	57.9%	110.74%
Common Stock	$417.6M	$415.0M	$407.1M
YoY Change	2.57%	2.33%	93.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$139.3M	$126.6M	$193.2M
YoY Change
Total Liabilities & Shareholders Equity	$157.9M	$143.1M	$213.1M
YoY Change	-25.91%	-40.7%	82.25%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2016 Q4
OPERATING ACTIVITIES
Net Income	$10.11M	-$20.72M	-$31.28M
YoY Change	-132.33%	-28.61%	83.98%
Depreciation, Depletion And Amortization	$670.0K	$730.0K	$400.0K
YoY Change	67.5%	170.37%	37.93%
Cash From Operating Activities	$4.700M	-$19.24M	-$26.56M
YoY Change	-117.7%	-22.48%	22.96%
INVESTING ACTIVITIES
Capital Expenditures	-$30.00K	-$420.0K	-$2.760M
YoY Change	-98.91%	-73.91%	513.33%
Acquisitions
YoY Change
Other Investing Activities	$11.25M	$15.23M	-$56.47M
YoY Change	-119.92%	-121.84%
Cash From Investing Activities	$11.22M	$14.81M	-$59.23M
YoY Change	-118.94%	-120.76%	13062.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.00K	260.0K	20.00K
YoY Change	-50.0%	-99.76%	100.0%
NET CHANGE
Cash From Operating Activities	4.700M	-19.24M	-26.56M
Cash From Investing Activities	11.22M	14.81M	-59.23M
Cash From Financing Activities	10.00K	260.0K	20.00K
Net Change In Cash	15.93M	-4.170M	-85.77M
YoY Change	-118.57%	-130.44%	289.16%
FREE CASH FLOW
Cash From Operating Activities	$4.700M	-$19.24M	-$26.56M
Capital Expenditures	-$30.00K	-$420.0K	-$2.760M
Free Cash Flow	$4.730M	-$18.82M	-$23.80M
YoY Change	-119.87%	-18.91%	12.53%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	47534979	shares
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	160360000
CY2017Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	11282000
CY2017Q3	us-gaap	Assets Current AssetsCurrent	133630000
CY2017Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	414970000
CY2017Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1723000
CY2017Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-10000
CY2017Q3	us-gaap	Assets Assets	143105000
CY2017Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	3000
CY2017Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	13000
CY2017Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0
CY2017Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	69834000
CY2017Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	69844000
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	59454000
CY2017Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2017Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	69834000
CY2017Q3	ardx	Cash Cash Equivalents And Short Term Investments Gross Unrealized Losses CashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedLosses	13000
CY2017Q3	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2017Q3	us-gaap	Liabilities Liabilities	16468000
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47503970	shares
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	143105000
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	15727000
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47503970	shares
CY2017Q3	us-gaap	Common Stock Value CommonStockValue	5000
CY2017Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	59454000
CY2017Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	129298000
CY2017Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2722000
CY2017Q3	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-288328000
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	126637000
CY2017Q3	ardx	Cash And Cash Equivalents Gross Unrealized Gains CashAndCashEquivalentsGrossUnrealizedGains	0
CY2017Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	700000
CY2017Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	853000
CY2017Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	741000
CY2017Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q3	us-gaap	Preferred Stock Value PreferredStockValue
CY2017Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4342000
CY2017Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8622000
CY2017Q3	ardx	Cash Cash Equivalents And Short Term Investments Fair Value Disclosure CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure	129288000
CY2017Q3	ardx	Accrued Contract Manufacturing Costs AccruedContractManufacturingCosts	2895000
CY2017Q3	ardx	Accrued Professional And Consultant Fees Current AccruedProfessionalAndConsultantFeesCurrent	761000
CY2017Q3	ardx	Cash Cash Equivalents And Short Term Investments Gross Unrealized Gains CashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGains	3000
CY2017Q3	ardx	Cash And Cash Equivalents Gross Unrealized Losses CashAndCashEquivalentsGrossUnrealizedLosses	0
CY2017Q3	ardx	Accrued Clinical And Nonclinical Expenses AccruedClinicalAndNonclinicalExpenses	6926000
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	107004000
CY2016Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	10405000
CY2016Q4	us-gaap	Assets Current AssetsCurrent	203992000
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	407092000
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5635000
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-71000
CY2016Q4	us-gaap	Assets Assets	213131000
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	7000
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	78000
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	126225000
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	126296000
CY2016Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	126225000
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	74598000
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47309422	shares
CY2016Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	74598000
CY2016Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	200894000
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47309422	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	5000
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3161000
CY2016Q4	us-gaap	Liabilities Liabilities	19980000
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	213131000
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19201000
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	684000
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	148000
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	779000
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3169000
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8991000
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-213875000
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	193151000
CY2016Q4	ardx	Cash And Cash Equivalents Gross Unrealized Gains CashAndCashEquivalentsGrossUnrealizedGains	0
CY2016Q4	ardx	Cash Cash Equivalents And Short Term Investments Gross Unrealized Losses CashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedLosses	78000
CY2016Q4	ardx	Cash Cash Equivalents And Short Term Investments Fair Value Disclosure CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure	200823000
CY2016Q4	ardx	Accrued Contract Manufacturing Costs AccruedContractManufacturingCosts	2705000
CY2016Q4	ardx	Accrued Professional And Consultant Fees Current AccruedProfessionalAndConsultantFeesCurrent	322000
CY2016Q4	ardx	Cash Cash Equivalents And Short Term Investments Gross Unrealized Gains CashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGains	7000
CY2016Q4	ardx	Cash And Cash Equivalents Gross Unrealized Losses CashAndCashEquivalentsGrossUnrealizedLosses	0
CY2016Q4	ardx	Accrued Clinical And Nonclinical Expenses AccruedClinicalAndNonclinicalExpenses	6694000
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7001000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6600000	shares
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-57000
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	360000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-15144000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-74392000
	us-gaap	Cost Of Services Amortization CostOfServicesAmortization	142000
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Depreciation Depreciation	1965000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.57
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1624000
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	61000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2327000
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	70384000
	dei	Entity Central Index Key EntityCentralIndexKey	0001437402
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	675000
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2017-09-30
	dei	Entity Registrant Name EntityRegistrantName	Ardelyx, Inc.
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17752000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-74453000
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-439000
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	839000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3182000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2380000
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	202000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	54069000
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-69888000
	us-gaap	Operating Expenses OperatingExpenses	76077000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	675000
	us-gaap	Net Income Loss NetIncomeLoss	-74453000
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
	us-gaap	Operating Income Loss OperatingIncomeLoss	-76077000
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> <b><i>Reclassification</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Approximately $0.2 million in the nine months ended September 30, 2016, which was previously recorded within “Proceeds from issuance of common stock under stock plans” in Financing activities in the Statement of Cash Flows, has been reclassified as a <font style="WHITE-SPACE: nowrap">non-cash</font> item “Issuance of common stock for services” within Operating activities.</p> </div>
	us-gaap	Proceeds From Sale Of Other Investments ProceedsFromSaleOfOtherInvestments	16857000
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	109923000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	58325000
	us-gaap	Share Based Compensation ShareBasedCompensation	7001000
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	200000
	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	46858	shares
	dei	Trading Symbol TradingSymbol	ARDX
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	47404039	shares
	us-gaap	Cost Of Services Amortization CostOfServicesAmortization	148000
	us-gaap	Depreciation Depreciation	904000
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Although management believes these estimates are based upon reasonable assumptions within the bounds of its knowledge of the Company’s business and operations, actual results could differ materially from those estimates.</p> </div>
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3767000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4600000	shares
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	11000
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	289000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	53356000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-81138000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.15
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13469000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-81113000
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-139000
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	6785000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2678000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-719000
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	187000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-71848000
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-65786000
	us-gaap	Operating Expenses OperatingExpenses	81420000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	190990000
	us-gaap	Net Income Loss NetIncomeLoss	-81113000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-81420000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	307000
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-25000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2108000
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	69740000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	190574000
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	416000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	67951000
	us-gaap	Share Based Compensation ShareBasedCompensation	3767000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37706045	shares
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1291000
CY2016Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4700000	shares
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29056000
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.65
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4337000
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29031000
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24863000
CY2017Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	30000
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	29200000
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-29031000
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-29200000
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	169000
CY2016Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-25000
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	44935126	shares
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2102000
CY2017Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7000000	shares
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20694000
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.44
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5860000
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20724000
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	21225000
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-20724000
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-21225000
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	501000
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15365000
CY2017Q3	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	0	shares
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	47464310	shares

Files In Submission

Name	View Source	Status
0001193125-17-334997-index-headers.html	Edgar Link	pending
0001193125-17-334997-index.html	Edgar Link	pending
0001193125-17-334997.txt	Edgar Link	pending
0001193125-17-334997-xbrl.zip	Edgar Link	pending
ardx-20170930.xml	Edgar Link	completed
ardx-20170930.xsd	Edgar Link	pending
ardx-20170930_cal.xml	Edgar Link	unprocessable
ardx-20170930_def.xml	Edgar Link	unprocessable
ardx-20170930_lab.xml	Edgar Link	unprocessable
ardx-20170930_pre.xml	Edgar Link	unprocessable
d469480d10q.htm	Edgar Link	pending
d469480dex101.htm	Edgar Link	pending
d469480dex311.htm	Edgar Link	pending
d469480dex312.htm	Edgar Link	pending
d469480dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ARDX
ARDELYX, INC. Stock $ardx

2017 Q4 Form 10-Q Financial Statement

#000119312517334997 Filed on November 07, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARDX ARDELYX, INC. Stock $ardx

2017 Q4 Form 10-Q Financial Statement

#000119312517334997 Filed on November 07, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARDX
ARDELYX, INC. Stock $ardx